Opinion|Videos|June 4, 2025
Novel Treatment Options for Bronchiectasis
Panelists discuss how emerging DPP1 inhibitor therapies target neutrophil serine proteases to reduce neutrophilic inflammation and neutrophil extracellular trap formation in bronchiectasis.
Advertisement
Episodes in this series
Clinical Brief: Emerging Therapies for Bronchiectasis
Main Discussion Topics
- DPP1 inhibitors target neutrophil inflammation in bronchiectasis.
- Eosinophilic bronchiectasis (approximately 30% of cases) benefits from targeted therapies.
- Approaches to treatment vary based on inflammatory phenotype.
Key Points for Physicians
- DPP1 inhibitors:
- Target abnormal neutrophil function and reduce neutrophil serine proteases
- May prevent formation of neutrophil extracellular traps
- Aim to reduce exacerbations and disease progression
- For eosinophilic bronchiectasis (30% of cases):
- Inhaled corticosteroids are beneficial
- Anti-IL5 therapies show promise
- Biologic therapies are being investigated
- Discourage inhaled corticosteroids in neutrophilic bronchiectasis (70% of cases) due to potential infection risk.
Notable Insights
Peripheral eosinophil counts may help guide treatment decisions similar to their use in chronic obstructive pulmonary disease management, with different thresholds being investigated.
Clinical Significance
Emerging therapies targeting specific inflammatory pathways show promise for more precise treatment of bronchiectasis based on inflammatory phenotype.
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5